Instructions Tivortin aspartate oral solution bottle 200 ml
Composition
active ingredient: L-arginine aspartate;
1 ml of solution contains L-arginine aspartate 200 mg;
excipients: sorbitol (E 420), sodium saccharin (E 954), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), food flavoring "Caramel", water for injections.
Dosage form
Oral solution.
Main physicochemical properties: slightly yellowish liquid with a caramel odor.
Pharmacotherapeutic group
Other cardiological drugs. Amino acids.
ATX code C01E.
Pharmacological properties
Pharmacodynamics
"Tivortin® aspartate" has antihypoxic, cytoprotective, antioxidant, detoxification, membrane-stabilizing effects. It plays an important role in the processes of ammonia neutralization and stimulation of its excretion from the body, enhances the detoxification function of the liver. It has a hepatoprotective effect, positively affects the processes of energy supply in hepatocytes.
As a nitric oxide donor, Tivortin® aspartate participates in the processes of energy supply of the body, reduces the activation and adhesion of leukocytes and platelets to the vascular endothelium, preventing the formation and development of atherosclerotic plaques, and is involved in the processes of fibrinogenolysis and spermatogenesis.
The drug has a moderate anabolic effect, stimulates the activity of the thymus gland, promotes insulin synthesis and regulates blood glucose levels during physical exertion, and helps correct acid-base balance.
Pharmacokinetics
Not studied.
Indication
Used in the complex therapy of atherosclerosis of the heart and brain vessels, arterial hypertension, atherosclerosis of peripheral vessels; chronic heart failure; hypercholesterolemia; chronic obstructive pulmonary diseases, pulmonary hypertension; asthenic conditions.
Contraindication
Hypersensitivity, severe renal impairment. Myocardial infarction (including history).
Interaction with other medicinal products and other types of interactions
When using arginine aspartate, it is necessary to take into account that the combined use of aminophylline with arginine may be accompanied by an increase in insulin levels in the blood, and spironolactone with arginine may be accompanied by an increase in potassium levels in the blood.
Arginine is incompatible with thiopental.
Application features
It should be used with caution in cases of electrolyte imbalance and kidney disease. When using the drug, it is necessary to adhere to a balanced sleep and rest regimen, and to avoid alcohol, nicotine, and psychostimulants. If symptoms of asthenia increase while taking the drug, treatment should be discontinued.
The drug should be used with caution in patients with angina pectoris.
Patients with hereditary fructose intolerance should not take the drug.
The medicine contains sorbitol (E 420) - if you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
The drug contains excipients such as methyl parahydroxybenzoate (E 218) and propyl parahydroxybenzoate (E 216), which may cause allergic reactions (possibly delayed).
This medicinal product contains less than 0.02 mmol (0.47 mg) sodium/dose (5 ml), i.e. essentially ‘sodium-free’.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Use during pregnancy or breastfeeding
The drug penetrates the placenta, so it can be used during pregnancy only if the expected benefit to the mother outweighs the potential risk to the fetus.
There are no data on the use of the drug during breastfeeding.
Method of administration and doses
To be used internally, take with meals. Adults with atherosclerosis of the vessels of the heart and brain, atherosclerosis of peripheral vessels – 5 ml (1 measuring spoon –
1 g of the drug) 3–8 times a day. For hypercholesterolemia, arterial hypertension – 5 ml
3–6 times a day. In chronic obstructive pulmonary diseases, pulmonary hypertension – 5 ml 3–6 times a day. In asthenic conditions – 5 ml 4–8 times a day. The maximum daily dose is 8 g. The duration of the course of treatment is 8–15 days; if necessary, the course of treatment is repeated.
Children
Do not use in patients under 18 years of age.
Overdose
Symptoms: hypersensitivity reactions, hypoglycemic states.
Treatment. If these symptoms occur, the drug should be discontinued. Gastric lavage and sorbents are indicated. There is no antidote. Symptomatic therapy.
Adverse reactions
Musculoskeletal system: joint pain.
On the part of the digestive tract: rarely - a feeling of mild discomfort in the stomach and intestines, nausea immediately after taking the drug, which disappear on their own.
Immune system disorders: hypersensitivity reactions, including bronchospasm.
Laboratory indicators: hyperkalemia.
Expiration date
2 years.
The shelf life after opening the bottle is 14 days.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children. Do not freeze.
Packaging
200 ml in a bottle; 1 bottle with a measuring spoon in a cardboard pack.
Vacation category
Without a prescription.
Producer
LLC "Yuria-Pharm".
Location of the manufacturer and its business address
Ukraine, 18030, Cherkasy region, Cherkasy city, Kobzarska st., 108.
